logo
Children living near oil and gas wells face higher risk of rare leukemia, studies show

Children living near oil and gas wells face higher risk of rare leukemia, studies show

Yahoo17-07-2025
Acute lymphocytic leukemia is one of the most commonly diagnosed cancers in children, although it is rare. It begins in the bone marrow and rapidly progresses.
Long-term survival rates exceed 90%, but many survivors face lifelong health challenges. Those include heart conditions, mental health struggles and a greater chance of developing a second cancer.
Overall cancer rates in the U.S. have declined since 2002, but childhood acute lymphocytic leukemia rates continue to rise. This trend underscores the need for prevention rather than focusing only on treatment for this disease.
A growing body of literature suggests exposure to the types of chemicals emitted from oil and natural gas wells increases the risk of developing childhood acute lymphocytic leukemia.
We are environmental epidemiologists focused on understanding the health implications of living near oil and natural gas development operations in Colorado and Pennsylvania. Both states experienced a rapid increase in oil and natural gas development in residential areas beginning in the early 21st century. We've studied this issue in these states, using different datasets and some different approaches.
2 studies, similar findings
Both of our studies used a case-control design. This design compares children with cancer, known as cases, with children without cancer, known as controls. We used data from statewide birth and cancer registries.
We also used specialized mapping techniques to estimate exposure to oil and natural gas development during sensitive time windows, such as pregnancy or early childhood.
The Colorado study looked at children born between 1992 and 2019. The study included 451 children diagnosed with leukemia and 2,706 children with no cancer diagnosis. It considered how many oil and natural gas wells were near a child's home and how intense the activity was at each well. Intensity of activity included the volume of oil and gas production and phase of well production.
The Colorado study found that children ages 2-9 living in areas with the highest density and intensity wells within eight miles (13 kilometers) of their home were at least two times more likely to be diagnosed with acute lymphocytic leukemia. Children with wells within three miles (five kilometers), of their home bore the greatest risk.
The Pennsylvania study looked at 405 children diagnosed with leukemia between 2009 and 2017 and 2,080 children without any cancer diagnosis. This study found that children living within 1.2 miles (two kilometers) of oil and natural gas wells at birth were two to three times more likely to be diagnosed with acute lymphocytic leukemia between ages 2 to 7 than those who lived farther than 1.2 miles away.
The risk of developing leukemia was more pronounced in children who were exposed during their mother's pregnancy.
The results of our two studies are also supported by a previous study in Colorado published in 2017. That study found children diagnosed with acute lymphocytic leukemia were four times more likely to live in areas with a high density of oil and natural gas wells than children diagnosed with other cancers.
Policy implications
To extract oil and natural gas from underground reserves, heavy drilling equipment injects water and chemicals into the earth under high pressure. Petroleum and contaminated wastewater are returned to the surface. It is well established that these activities can emit cancer-causing chemicals. Those include benzene, as well as other pollutants, to the air and water.
The U.S. is the world's largest producer of oil and natural gas. There are almost 1 million producing wells across the country, and many of these are located in or near residential areas. This puts millions of children at increased risk of exposure to cancer-causing chemicals.
In the U.S., oil and natural gas development is generally regulated at the state level. Policies aimed at protecting public health include establishing minimum distances between a new well and existing homes, known as a setback distance. These policies also include requirements for emission control technologies on new and existing wells and restrictions on the construction of new wells.
Setbacks offer a powerful solution to reduce noise, odors and other hazards experienced by communities near oil and gas wells. However, it is challenging to establish a universal setback that optimally addresses all hazards. That's because noise, air pollutants and water contaminants dissipate at different rates depending on location and other factors.
In addition, setbacks focus exclusively on where to place oil and natural gas wells but do not impose any restrictions on releases of air pollutants or greenhouse gases. Therefore, they do not address regional air quality issues or mitigate climate change.
Furthermore, current U.S. setback distances range from just 200 feet to 3,200 feet. Our results indicate that even the largest setback of 3,200 feet (one kilometer) is not sufficient to protect children from an increased leukemia risk.
Our results support a more comprehensive policy approach that considers both larger setback distances and mandatory monitoring and control of hazardous emissions on both new and existing wells.
Future research
More research is needed in other states, such as Texas and California, that have oil and natural gas development in residential areas, as well as on other pediatric cancers.
One such cancer is acute myeloid leukemia. This is another type of leukemia that starts in bone marrow and rapidly progresses. This cancer has exhibited a strong link to benzene exposure in adult workers in several industries, including the petroleum industry. Researchers have also documented a moderate cancer link for children exposed to vehicular benzene.
It remains unclear whether benzene is the culprit or if another agent or combination of hazards is an underlying cause of acute myeloid leukemia.
Even though questions remain, we believe the existing evidence coupled with the seriousness of childhood acute lymphocytic leukemia supports enacting further protective measures. We also believe policymakers should consider the cumulative effects from wells, other pollution sources and socioeconomic stressors on children and communities.
Read more of our stories about Colorado and Pennsylvania.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Lisa McKenzie, University of Colorado Anschutz Medical Campus and Nicole Deziel, Yale University
Read more:
Oil and gas communities are a blind spot in America's climate and economic policies
How weakened US fossil fuel regulations threaten environmental justice in Colorado
Coloradans reject restrictions on drilling distances from homes and schools
Lisa McKenzie receives funding from the American Cancer Society and the University of Colorado Cancer Center.
Nicole Deziel receives funding from the American Cancer Society, the National Institutes of Health, and the Yale School of Public Health.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

Yahoo

time5 minutes ago

  • Yahoo

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

time5 minutes ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

More than 20% of NASA's workforce requests to leave agency
More than 20% of NASA's workforce requests to leave agency

CBS News

time7 minutes ago

  • CBS News

More than 20% of NASA's workforce requests to leave agency

Nearly 4,000 employees, or more than 20% of NASA's workforce, have applied to leave the agency, NASA confirmed to CBS News Friday. About 3,870 employees have applied to depart NASA over two rounds through the Trump administration's deferred resignation program, NASA disclosed. The deadline for applications to the program is midnight Friday. With those deferred resignations, NASA's civil servant workforce would shrink from about 18,000 to 14,000 personnel. This figure also includes about 500 employees who were lost through normal attrition, the agency said. "Safety remains a top priority for our agency as we balance the need to become a more streamlined and more efficient organization and work to ensure we remain fully capable of pursuing a Golden Era of exploration and innovation, including to the Moon and Mars," NASA spokesperson Cheryl Warner said in a statement. According to NASA, about 870 employees applied to leave during the first round of the Deferred Resignation Program, and about 3,000 employees during the second round. The deferred resignation program was a buyout program introduced across the federal government by the White House's Department of Government Efficiency at the onset of the Trump administration in an effort to slash costs and reduce the size of the federal workforce. A White House budget proposal issued in May would see NASA's funding cut by about 25% for fiscal year 2026, from about $24 billion to $18 billion. NASA has also been roiled by a leadership crisis in recent months. In December, President Trump nominated billionaire private astronaut Jared Isaacman, a friend of former DOGE head Elon Musk, to serve as NASA's next administrator. Musk's SpaceX has several NASA contracts. However, in late May, Mr. Trump pulled Isaacman's nomination just ahead of the Senate confirmation vote, which was followed days later by a public fallout between Mr. Trump and Musk. Earlier this month, the president announced that Transportation Secretary Sean Duffy would temporarily lead the agency. Miles Doran contributed to this report.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store